Riccardo Lencioni, MD, FSIR, EBIR, discusses unmet needs in unresectable hepatocellular carcinoma.
Riccardo Lencioni, MD
Advertisement
Articles by Riccardo Lencioni, MD
Riccardo Lencioni, MD, FSIR, EB, discusses the EMERALD-1 trial of TACE/durvalumab/bevacizumab in patients with unresectable hepatocellular carcinoma.
Riccardo Lencioni, MD, professor in the department of radiology at the University of Pisa School of Medicine in Pisa, Italy, discusses how response to hepatocellular carcinoma (HCC) treatment can be best assessed in patients.
Advertisement
Latest Updated Articles
Dr Lencioni on the Results of the EMERALD-1 Trial in Unresectable HCCPublished: January 19th 2024 | Updated:
Dr. Lencioni on Assessing Response to HCC TherapyPublished: September 16th 2018 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Daratumumab and Hyaluronidase Plus VRd for Newly Diagnosed Multiple Myeloma
2
PD-L1 Expression Is More Predictive of Response to Pembrolizumab on Metastatic Sites in High-Grade Serous Ovarian Cancer
3
Lurbinectedin-Based Triplet Shows Clinical Benefit in Advanced Soft Tissue Sarcoma
4
Ultra-Sensitive ctDNA and CSF Liquid Biopsy May Refine Monitoring and Adaptive Trial Designs in Metastatic Breast Cancer
5